Aileron Therapeutics (ALRN)
(Delayed Data from NSDQ)
$3.73 USD
+0.82 (28.18%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.83 +0.10 (2.68%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.73 USD
+0.82 (28.18%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.83 +0.10 (2.68%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Zacks News
Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?
by Zacks Equity Research
Here is how Sensus Healthcare, Inc. (SRTS) and Aileron Therapeutics, Inc. (ALRN) have performed compared to their sector so far this year.
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Aileron Therapeutics (ALRN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
by Zacks Equity Research
Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Aileron Therapeutics, Inc. (ALRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.
Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
New Strong Sell Stocks for December 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for December 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for November 24th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for November 19th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
Aileron Therapeutics (ALRN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
5 Biotech Stocks Up More Than 100% This Year So Far
by Zacks Equity Research
Here we discuss five biotech companies recording impressive growth so far in 2020.
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics
5 Top Stocks Up 100%+ in May With More Room to Run
by Tirthankar Chakraborty
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
Aileron Therapeutics, Inc. (ALRN) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aileron Inks Collaboration Deal With Pfizer for Cancer Combo
by Zacks Equity Research
Aileron Therapeutics (ALRN) signs a clinical trial collaboration contract with Pfizer to study the combo of Aileron's ALRN-6924 and Pfizer's Ibrance for treating MDM2-amplified cancers. Stock rises.